BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Starosta A, Konieczny P. Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. Cell Mol Life Sci 2021;78:4867-91. [PMID: 33825942 DOI: 10.1007/s00018-021-03821-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Thapa S, Elhadidy S, Asakura A. Vascular therapy for Duchenne muscular dystrophy (DMD). Fac Rev 2023;12:3. [PMID: 36873982 DOI: 10.12703/r/12-3] [Reference Citation Analysis]
2 Den Hartog L, Asakura A. Implications of notch signaling in duchenne muscular dystrophy. Front Physiol 2022;13:984373. [DOI: 10.3389/fphys.2022.984373] [Reference Citation Analysis]
3 Fan S, Huang X, Tong H, Hong H, Lai Z, Hu W, Liu X, Zhang L, Jiang Z, Yu Q. p-TAK1 acts as a switch between myoblast proliferation phase and differentiation phase in mdx mice via regulating HO-1 expression. Eur J Pharmacol 2022;933:175277. [PMID: 36113553 DOI: 10.1016/j.ejphar.2022.175277] [Reference Citation Analysis]
4 Kaziród K, Myszka M, Dulak J, Łoboda A. Hydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseases. Cell Mol Life Sci 2022;79:608. [PMID: 36441348 DOI: 10.1007/s00018-022-04636-0] [Reference Citation Analysis]
5 Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study. Adv Ther 2022;39:3308-15. [PMID: 35614293 DOI: 10.1007/s12325-022-02179-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Markati T, De Waele L, Schara-Schmidt U, Servais L. Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy. Front Pharmacol 2021;12:735912. [PMID: 34790118 DOI: 10.3389/fphar.2021.735912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Ohlendieck K, Swandulla D. Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy. Pflugers Arch 2021;473:1813-39. [PMID: 34553265 DOI: 10.1007/s00424-021-02623-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Boukhatmi H. Drosophila, an Integrative Model to Study the Features of Muscle Stem Cells in Development and Regeneration. Cells 2021;10:2112. [PMID: 34440881 DOI: 10.3390/cells10082112] [Reference Citation Analysis]
9 Ogundele M, Zhang JS, Goswami MV, Barbieri ML, Dang UJ, Novak JS, Hoffman EP, Nagaraju K, Cinrg-Dnhs Investigators, Hathout Y. Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy. Life (Basel) 2021;11:827. [PMID: 34440571 DOI: 10.3390/life11080827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Gargan S, Dowling P, Zweyer M, Reimann J, Henry M, Meleady P, Swandulla D, Ohlendieck K. Mass Spectrometric Profiling of Extraocular Muscle and Proteomic Adaptations in the mdx-4cv Model of Duchenne Muscular Dystrophy. Life (Basel) 2021;11:595. [PMID: 34206383 DOI: 10.3390/life11070595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]